サンプル依頼リスト カート
  • English
  • Korean
デフォルト表紙
市場調査レポート
商品コード
1539302

リポソーム市場：世界の産業分析、規模、シェア、成長、動向、予測、2024年～2033年

Liposomes Market: Global Industry Analysis, Size, Share, Growth, Trends, and Forecast, 2024-2033

出版日
ページ情報
英文 201 Pages
納期
2～5営業日
カスタマイズ可能
価格
価格表記: USDを日本円(税抜)に換算
本日の銀行送金レート: 1USD=144.06円
リポソーム市場：世界の産業分析、規模、シェア、成長、動向、予測、2024年～2033年
出版日: 2024年08月16日
発行: Persistence Market Research
ページ情報: 英文 201 Pages
納期: 2～5営業日
GIIご利用のメリット
  • 全表示
  • 概要
  • 目次
概要

Persistence Market Researchはこのほど、世界のリポソーム市場に関する包括的なレポートを発表しました。当レポートでは、促進要因、新たな動向、機会、課題など、重要な市場力学を詳細に分析し、市場展望の詳細な理解を提供します。

主要な洞察

  • リポソーム市場規模（2024年）：75億6,690万米ドル
  • 予測市場金額（2033年）：130億2,960万米ドル
  • 世界市場成長率（CAGR 2024年～2033年）：6.2%

リポソーム市場 - レポート範囲：

リポソームはリン脂質で構成される球状の小胞で、親水性物質と疎水性物質の両方を封入できることから、ドラッグデリバリー・システムとして広く利用されています。これらのキャリアは、バイオアベイラビリティ、安定性、標的デリバリーを改善することで、ドラッグの治療効果と安全性を高めます。リポソーム市場は、医薬品、化粧品、食品産業における用途の拡大により、大幅な成長を遂げています。リポソーム技術の進歩、標的ドラッグデリバリーシステムに対する需要の高まり、慢性疾患の有病率の増加は、市場を前進させる主要な要因です。

市場成長の促進要因：

世界のリポソーム市場は、効果的なドラッグデリバリーシステムに対する需要の増加、がんや心血管疾患などの慢性疾患の増加など、いくつかの主要な要因によって促進されています。毒性を低減し、薬物の標的性を高めるリポソーム製剤の能力により、がん治療におけるリポソーム製剤への選好が高まっていることは、重要な成長促進要因です。さらに、リポソーム製造技術の進歩や、化粧品や栄養補助食品へのリポソーム応用の拡大も市場成長に寄与しています。

市場抑制要因：

リポソーム市場はその潜在性にもかかわらず、高い製造コストや複雑な製造工程といった課題に直面しています。リポソーム製剤の開発には高度な技術と専門知識が必要であるため、その普及が制限される可能性があります。さらに、規制上のハードルや、安全性と有効性を確保するための大規模な臨床試験の必要性も、メーカーが直面する課題に拍車をかけています。こうした課題に対処するためには、製造工程の最適化、コスト削減、規制基準の遵守が必要となります。

市場機会：

リポソーム市場は、技術の進歩と研究開発投資の増加により、大きな成長機会をもたらしています。新規のリポソームベースのドラッグデリバリーシステムと、遺伝子治療や免疫療法などの新たな治療領域との融合は、市場拡大の新たな道を開くと期待されています。個別化医療が重視されるようになり、標的治療のためのリポソーム製剤の市場開拓は、市場プレーヤーに有利な機会を提供します。戦略的提携、リポソーム技術の革新、新規用途の開拓は、こうした機会を生かし、市場の成長を促進するために不可欠です。

本レポートで扱う主要な質問

  • リポソーム市場の世界の成長を促進する主要な要因は何か？
  • リポソームベースのドラッグデリバリーシステムの採用を促進している治療分野と用途は？
  • 技術の進歩はリポソーム市場の競合情勢をどのように変えているか？
  • リポソーム市場の主要企業はどこで、競争力を維持するためにどのような戦略を採用しているのか？
  • 世界のリポソーム市場の新たな動向と将来性は？

目次

第1章 エグゼクティブサマリー

第2章 市場概要

  • 市場範囲 / 分類
  • 市場の定義 / 範囲 / 制限
  • 包含事項・除外事項

第3章 主要な市場動向

  • 市場に影響を与える主要な動向
  • 製品イノベーション / 開発動向

第4章 主要な成功要因

  • プロモーション戦略 - メーカー別
  • 製品採用率 - 主要統計
  • パイプライン評価
  • 規制シナリオ
  • PESTEL分析
  • ポーターの分析

第5章 市場背景

  • マクロ経済要因
  • 予測要因 - 関連性と影響
  • 市場力学

第6章 COVID-19危機分析

  • COVID-19と影響分析
    • 製品別
    • 用途別
    • 流通チャネル別
    • 地域別
  • 2024年の市場シナリオ

第7章 世界市場の需要（金額、百万米ドル）分析

  • 過去の市場金額（百万米ドル）分析、2019年～2023年
  • 現在および将来の市場金額（百万米ドル）の分析と予測、2024年～2033年
    • 前年比成長動向分析
    • 絶対額の機会分析

第8章 世界市場分析：製品別

  • イントロダクション / 主要な調査結果
  • 過去の市場規模（百万米ドル）分析：製品別、2019年～2023年
  • 現在および将来の市場規模（百万米ドル）の分析と予測：製品別、2024年～2033年
    • 単純リポソーム
    • 処方リポソーム
    • ワクチン
  • 市場の魅力分析：製品別

第9章 世界市場分析：用途別

  • イントロダクション / 主要な調査結果
  • 過去の市場規模（百万米ドル）分析：用途別、2019年～2023年
  • 現在および将来の市場規模（百万米ドル）の分析と予測：用途別、2024年～2033年
    • ドラッグデリバリー
    • 遺伝子導入 / トランスフェクション
    • 医療用画像診断用造影剤
    • 細胞膜のモデル
  • 市場の魅力分析：用途別

第10章 世界市場分析：流通チャネル別

  • イントロダクション / 主要な調査結果
  • 過去の市場規模（百万米ドル）分析：流通チャネル別、2019年～2023年
  • 現在および将来の市場規模（百万米ドル）の分析と予測：流通チャネル別、2024年～2033年
    • 小売販売
    • 流通販売
  • 市場の魅力分析：流通チャネル別

第11章 世界市場分析：地域別

  • イントロダクション
  • 過去の市場規模（百万米ドル）の分析：地域別、2019年～2023年
  • 現在および将来の市場金額（百万米ドル）分析と予測：地域別、2024年～2033年
    • 北米
    • ラテンアメリカ
    • 欧州
    • 東アジア
    • 南アジア
    • オセアニア
    • 中東・アフリカ（MEA）
  • 市場の魅力分析：地域別

第12章 北米市場分析

第13章 ラテンアメリカ市場分析

第14章 欧州市場分析

第15章 東アジア市場分析

第16章 南アジア市場分析

第17章 オセアニア市場

第18章 中東・アフリカ（MEA）市場分析

第19章 市場構造分析

  • 市場分析：企業階層別
  • 主要企業の市場シェア分析
  • 市場プレゼンス分析

第20章 競合分析

  • 競合ダッシュボード
  • ブランディングとプロモーション戦略
  • 主要開発分析
  • 競合の詳細情報
    • Novartis AG（Liposoma BV）
    • Precision NanoSystems Inc
    • Janssen Pharmaceutical Companies（Johnson &Johnson）
    • Encapsula Nano Sciences
    • Synpac-Kingdom Pharmaceutical Co., Ltd
    • Celsion GmbH
    • Gilead Sciences, Inc
    • Pacira BioSciences, Inc.
    • Luye Pharma Group
    • Sun Pharma Industries Ltd
    • Shanghai New Asia Pharmaceutical Co., Ltd.
    • ENERGY DELIVERY SOLUTIONs
    • Creative Biolabs
    • Nanovex Biotechnologies SL
    • Insys Therapeutics Inc
    • Fujifilm Holdings Corporation
    • Virpax Pharmaceuticals
    • Azaya Therapeutics
    • Avanti Polar Lipids, Inc.
    • Breath Therapeutics（Zambon company）
    • Getwell
    • Taiwan Liposome Company Ltd
    • Fresenius Health Care Group
    • Xellia Pharmaceuticals（Novo Holdings A/S）
    • Jazz Pharmaceuticals plc
    • Ipsen Biopharmaceuticals, Inc.
    • Baxter
    • GMPriority Pharma
    • SG Biopharm Pvt. Ltd

第21章 使用される前提条件と頭字語

第22章 調査手法

目次
Product Code: PMRREP16546

Persistence Market Research has recently unveiled a comprehensive report on the global Liposomes Market. This report provides an in-depth analysis of critical market dynamics, including driving factors, emerging trends, opportunities, and challenges, offering a detailed understanding of the market landscape.

Key Insights:

  • Liposomes Market Size (2024E): USD 7566.9 Mn
  • Projected Market Value (2033F): USD 13029.6 Mn
  • Global Market Growth Rate (CAGR 2024 to 2033): 6.2%

Liposomes Market - Report Scope:

Liposomes are spherical vesicles composed of phospholipids, which are widely used as drug delivery systems due to their ability to encapsulate both hydrophilic and hydrophobic substances. These carriers enhance the therapeutic efficacy and safety of drugs by improving their bioavailability, stability, and targeted delivery. The liposomes market is witnessing substantial growth driven by their increasing applications in pharmaceuticals, cosmetics, and food industries. Advancements in liposome technology, rising demand for targeted drug delivery systems, and the growing prevalence of chronic diseases are key factors propelling the market forward.

Market Growth Drivers:

The global Liposomes Market is driven by several key factors, including the increasing demand for effective drug delivery systems and the rise in chronic diseases such as cancer and cardiovascular disorders. The growing preference for liposomal formulations in cancer therapy, owing to their ability to reduce toxicity and enhance drug targeting, is a significant growth driver. Additionally, advancements in liposome manufacturing technologies and the expansion of liposome applications in cosmetics and nutraceuticals are contributing to market growth.

Market Restraints:

Despite its potential, the Liposomes Market faces challenges such as high production costs and complex manufacturing processes. The development of liposomal formulations requires sophisticated technology and expertise, which can limit their widespread adoption. Moreover, regulatory hurdles and the need for extensive clinical trials to ensure safety and efficacy add to the challenges faced by manufacturers. Addressing these challenges involves optimizing production processes, reducing costs, and ensuring compliance with regulatory standards.

Market Opportunities:

The Liposomes Market presents significant growth opportunities driven by technological advancements and increasing investment in research and development. The integration of novel liposome-based drug delivery systems with emerging therapeutic areas such as gene therapy and immunotherapy is expected to open new avenues for market expansion. The growing emphasis on personalized medicine and the development of liposomal formulations for targeted therapies offer lucrative opportunities for market players. Strategic collaborations, innovation in liposome technology, and the exploration of new applications are essential for capitalizing on these opportunities and driving market growth.

Key Questions Answered in the Report:

  • What are the primary factors driving the growth of the Liposomes Market globally?
  • Which therapeutic areas and applications are leading the adoption of liposome-based drug delivery systems?
  • How are technological advancements reshaping the competitive landscape of the Liposomes Market?
  • Who are the key players in the Liposomes Market, and what strategies are they employing to stay competitive?
  • What are the emerging trends and future prospects in the global Liposomes Market?

Competitive Intelligence and Business Strategy:

Leading players in the global Liposomes Market, such as Gilead Sciences, Inc., Johnson & Johnson, and Novartis AG, focus on innovation, technological advancements, and strategic collaborations to gain a competitive edge. These companies invest heavily in R&D to develop cutting-edge liposomal formulations that offer enhanced drug delivery capabilities and reduced side effects. Partnerships with research institutions, biotechnology firms, and pharmaceutical companies facilitate market access and promote the adoption of liposome-based therapies. Emphasizing patient-centric approaches, robust regulatory compliance, and the development of cost-effective solutions are key strategies for maintaining market leadership in the dynamic Liposomes Market landscape.

Key Companies Profiled:

  • Novartis AG (Liposoma BV)
  • Precision NanoSystems Inc
  • Janssen Pharmaceutical Companies (Johnson & Johnson)
  • Encapsula Nano Sciences
  • Synpac-Kingdom Pharmaceutical Co., Ltd
  • Celsion GmbH
  • Gilead Sciences, Inc
  • Pacira BioSciences, Inc.
  • Luye Pharma Group
  • Sun Pharma Industries Ltd
  • Shanghai New Asia Pharmaceutical Co., Ltd.
  • ENERGY DELIVERY SOLUTIONs
  • Creative Biolabs
  • Nanovex Biotechnologies SL
  • Insys Therapeutics Inc
  • Fujifilm Holdings Corporation
  • Virpax Pharmaceuticals
  • Azaya Therapeutics
  • Avanti Polar Lipids, Inc.
  • Breath Therapeutics (Zambon company)
  • Getwell
  • Taiwan Liposome Company Ltd
  • Fresenius Health Care Group
  • Xellia Pharmaceuticals (Novo Holdings A/S)
  • Jazz Pharmaceuticals plc
  • Ipsen Biopharmaceuticals, Inc.
  • Baxter
  • GMPriority Pharma
  • S. G. Biopharm Pvt. Ltd

Key Segments Covered in Liposomes Industry Research

Product:

  • Simple Liposomes
  • Formulated Liposomes
  • Vaccines

Application:

  • Drug delivery
  • Gene Delivery/Transfection
  • Contrast agents for medical imaging
  • Model Cell Membranes

Distribution Channel:

  • Retail Sales
  • Distributional Sales

Region:

  • North America
  • Latin America
  • Europe
  • South Asia
  • East Asia
  • Oceania
  • Middle East & Africa

Table of Contents

1. Executive Summary

  • 1.1. Global Market Outlook
  • 1.2. Demand Side Trends
  • 1.3. Supply Side Trends
  • 1.4. Analysis and Recommendations

2. Market Overview

  • 2.1. Market Coverage / Taxonomy
  • 2.2. Market Definition / Scope / Limitations
  • 2.3. Inclusions and Exclusions

3. Key Market Trends

  • 3.1. Key Trends Impacting the Market
  • 3.2. Product Innovation / Development Trends

4. Key Success Factors

  • 4.1. Promotional Strategies - By Manufacturers
  • 4.2. Product Adoption Rate - Key Statistics
  • 4.3. Pipeline Assessment
  • 4.4. Regulatory Scenario
  • 4.5. PESTEL Analysis
  • 4.6. Porter's Analysis

5. Market Background

  • 5.1. Macro-Economic Factors
    • 5.1.1. Global GDP Growth Outlook
    • 5.1.2. Global Healthcare Outlook
    • 5.1.3. Global Drug Delivery Systems Market Outlook
  • 5.2. Forecast Factors - Relevance & Impact
    • 5.2.1. Prevalence of Chronic Diseases
    • 5.2.2. Growing Demand for Liposomal Drugs
    • 5.2.3. Widespread Adoption as Nano - Carriers for Diverse Pharmaceutical Applications
    • 5.2.4. Increasing Research and Development Activities
    • 5.2.5. Technological Advancements
    • 5.2.6. Merger and Acquisitions
  • 5.3. Market Dynamics
    • 5.3.1. Drivers
    • 5.3.2. Restraints
    • 5.3.3. Opportunity Analysis

6. COVID-19 Crisis Analysis

  • 6.1. COVID-19 and Impact Analysis
    • 6.1.1. By Product
    • 6.1.2. By Application
    • 6.1.3. By Distribution Channel
    • 6.1.4. By Region
  • 6.2. 2024 Market Scenario

7. Global Market Demand (in Value US$ Mn) Analysis 2019-2023 and Forecast, 2024-2033

  • 7.1. Historical Market Value (US$ Mn) Analysis, 2019-2023
  • 7.2. Current and Future Market Value (US$ Mn) Analysis and Forecast, 2024-2033
    • 7.2.1. Y-o-Y Growth Trend Analysis
    • 7.2.2. Absolute $ Opportunity Analysis

8. Global Market Analysis 2019-2023 and Forecast 2024-2033, By Product

  • 8.1. Introduction / Key Findings
  • 8.2. Historical Market Size (US$ Mn) Analysis, by Product, 2019-2023
  • 8.3. Current and Future Market Size (US$ Mn) Analysis and Forecast, by Product, 2024-2033
    • 8.3.1. Simple Liposomes
    • 8.3.2. Formulated Liposomes
      • 8.3.2.1. Doxorubicin Liposomes
      • 8.3.2.2. Amphotericin B Liposomes
      • 8.3.2.3. Paclitaxel Liposomes
      • 8.3.2.4. Cytarabine Liposomes
      • 8.3.2.5. Irinotecan Liposomes
      • 8.3.2.6. Cisplatin Liposomes
      • 8.3.2.7. Others
    • 8.3.3. Vaccines
  • 8.4. Market Attractiveness Analysis, by Product

9. Global Market Analysis 2019-2023 and Forecast 2024-2033, By Application

  • 9.1. Introduction / Key Findings
  • 9.2. Historical Market Size (US$ Mn) Analysis, By Application, 2019-2023
  • 9.3. Current and Future Market Size (US$ Mn) Analysis and Forecast, by Application, 2024-2033
    • 9.3.1. Drug delivery
      • 9.3.1.1. Cancer
      • 9.3.1.2. Fungal Infection
      • 9.3.1.3. Viral & Parasite Infection
      • 9.3.1.4. Others
    • 9.3.2. Gene Delivery/Transfection
    • 9.3.3. Contrast agents for medical imaging
    • 9.3.4. Model Cell Membranes
  • 9.4. Market Attractiveness Analysis, by Application

10. Global Market Analysis 2019-2023 and Forecast 2024-2033, By Distribution Channel

  • 10.1. Introduction / Key Findings
  • 10.2. Historical Market Size (US$ Mn) Analysis, By Distribution Channel, 2019-2023
  • 10.3. Current and Future Market Size (US$ Mn) Analysis and Forecast, by Distribution Channel, 2024-2033
    • 10.3.1. Retail Sales
      • 10.3.1.1. Academic & Research Laboratories
      • 10.3.1.2. Biopharmaceutical Companies
      • 10.3.1.3. Clinical Research Organizations
      • 10.3.1.4. Others
    • 10.3.2. Distributional Sales
      • 10.3.2.1. Hospital Pharmacies
      • 10.3.2.2. Retail Pharmacies
      • 10.3.2.3. Mail Order Pharmacies
      • 10.3.2.4. Drug Stores
  • 10.4. Market Attractiveness Analysis, by Distribution Channel

11. Global Market Analysis 2019-2023 and Forecast 2024-2033, By Region

  • 11.1. Introduction
  • 11.2. Historical Market Size (US$ Mn) Analysis, by Region, 2019-2023
  • 11.3. Current and Future Market Value (US$ Mn) Analysis and Forecast, by Region 2024-2033
    • 11.3.1. North America
    • 11.3.2. Latin America
    • 11.3.3. Europe
    • 11.3.4. East Asia
    • 11.3.5. South Asia
    • 11.3.6. Oceania
    • 11.3.7. Middle East and Africa (MEA)
  • 11.4. Market Attractiveness Analysis, by Region

12. North America Market Analysis 2019-2023 and Forecast 2024-2033

  • 12.1. Introduction
  • 12.2. Historical Market Size (US$ Mn) Trend Analysis, by Market Taxonomy, 2019-2023
  • 12.3. Current and Future Market Value (US$ Mn) Analysis and Forecast, by Market Taxonomy 2024-2033
    • 12.3.1. By Country
      • 12.3.1.1. U.S.
      • 12.3.1.2. Canada
    • 12.3.2. By Product
    • 12.3.3. By Application
    • 12.3.4. By Distribution Channel
  • 12.4. Market Attractiveness Analysis
    • 12.4.1. By Country
    • 12.4.2. By Product
    • 12.4.3. By Application
    • 12.4.4. By Distribution Channel
  • 12.5. Market Trends
  • 12.6. Drivers and Restraints - Impact Analysis
  • 12.7. Country Level Analysis & Forecast
    • 12.7.1. U.S. Market Analysis
      • 12.7.1.1. Introduction
      • 12.7.1.2. Market Analysis and Forecast, by Market Taxonomy
        • 12.7.1.2.1. By Product
        • 12.7.1.2.2. By Application
        • 12.7.1.2.3. By Distribution Channel
    • 12.7.2. Canada Market Analysis
      • 12.7.2.1. Introduction
      • 12.7.2.2. Market Analysis and Forecast, by Market Taxonomy
        • 12.7.2.2.1. By Product
        • 12.7.2.2.2. By Application
        • 12.7.2.2.3. By Distribution Channel

13. Latin America Market Analysis 2019-2023 and Forecast 2024-2033

  • 13.1. Introduction
  • 13.2. Historical Market Size (US$ Mn) Trend Analysis, by Market Taxonomy, 2019-2023
  • 13.3. Current and Future Market Value (US$ Mn) Analysis and Forecast, by Market Taxonomy 2024-2033
    • 13.3.1. By Country
      • 13.3.1.1. Mexico
      • 13.3.1.2. Brazil
      • 13.3.1.3. Argentina
      • 13.3.1.4. Rest of Latin America
    • 13.3.2. By Product
    • 13.3.3. By Application
    • 13.3.4. By Distribution Channel
  • 13.4. Market Attractiveness Analysis
    • 13.4.1. By Country
    • 13.4.2. By Product
    • 13.4.3. By Application
    • 13.4.4. By Distribution Channel
  • 13.5. Market Trends
  • 13.6. Drivers and Restraints - Impact Analysis
  • 13.7. Country Level Analysis & Forecast
    • 13.7.1. Mexico Market Analysis
      • 13.7.1.1. Introduction
      • 13.7.1.2. Market Analysis and Forecast, by Market Taxonomy
        • 13.7.1.2.1. By Product
        • 13.7.1.2.2. By Application
        • 13.7.1.2.3. By Distribution Channel
    • 13.7.2. Brazil Market Analysis
      • 13.7.2.1. Introduction
      • 13.7.2.2. Market Analysis and Forecast, by Market Taxonomy
        • 13.7.2.2.1. By Product
        • 13.7.2.2.2. By Application
        • 13.7.2.2.3. By Distribution Channel
    • 13.7.3. Argentina Market Analysis
      • 13.7.3.1. Introduction
      • 13.7.3.2. Market Analysis and Forecast, by Market Taxonomy
        • 13.7.3.2.1. By Product
        • 13.7.3.2.2. By Application
        • 13.7.3.2.3. By Distribution Channel

14. Europe Market Analysis 2019-2023 and Forecast 2024-2033

  • 14.1. Introduction
  • 14.2. Historical Market Size (US$ Mn) Trend Analysis, by Market Taxonomy, 2019-2023
  • 14.3. Current and Future Market Value (US$ Mn) Analysis and Forecast, by Market Taxonomy 2024-2033
    • 14.3.1. By Country
      • 14.3.1.1. Germany
      • 14.3.1.2. Italy
      • 14.3.1.3. France
      • 14.3.1.4. U.K.
      • 14.3.1.5. Spain
      • 14.3.1.6. BENELUX
      • 14.3.1.7. Russia
      • 14.3.1.8. Rest of Europe
    • 14.3.2. By Product
    • 14.3.3. By Application
    • 14.3.4. By Distribution Channel
  • 14.4. Market Attractiveness Analysis
    • 14.4.1. By Country
    • 14.4.2. By Product
    • 14.4.3. By Application
    • 14.4.4. By Distribution Channel
  • 14.5. Market Trends
  • 14.6. Drivers and Restraints - Impact Analysis
  • 14.7. Country Level Analysis & Forecast
    • 14.7.1. Germany Market Analysis
      • 14.7.1.1. Introduction
      • 14.7.1.2. Market Analysis and Forecast, by Market Taxonomy
        • 14.7.1.2.1. By Product
        • 14.7.1.2.2. By Application
        • 14.7.1.2.3. By Distribution Channel
    • 14.7.2. Italy Market Analysis
      • 14.7.2.1. Introduction
      • 14.7.2.2. Market Analysis and Forecast, by Market Taxonomy
        • 14.7.2.2.1. By Product
        • 14.7.2.2.2. By Application
        • 14.7.2.2.3. By Distribution Channel
    • 14.7.3. France Market Analysis
      • 14.7.3.1. Introduction
      • 14.7.3.2. Market Analysis and Forecast, by Market Taxonomy
        • 14.7.3.2.1. By Product
        • 14.7.3.2.2. By Application
        • 14.7.3.2.3. By Distribution Channel
    • 14.7.4. U.K. Market Analysis
      • 14.7.4.1. Introduction
      • 14.7.4.2. Market Analysis and Forecast, by Market Taxonomy
        • 14.7.4.2.1. By Product
        • 14.7.4.2.2. By Application
        • 14.7.4.2.3. By Distribution Channel
    • 14.7.5. Spain Market Analysis
      • 14.7.5.1. Introduction
      • 14.7.5.2. Market Analysis and Forecast, by Market Taxonomy
        • 14.7.5.2.1. By Product
        • 14.7.5.2.2. By Application
        • 14.7.5.2.3. By Distribution Channel
    • 14.7.6. BENELUX Market Analysis
      • 14.7.6.1. Introduction
      • 14.7.6.2. Market Analysis and Forecast, by Market Taxonomy
        • 14.7.6.2.1. By Product
        • 14.7.6.2.2. By Application
        • 14.7.6.2.3. By Distribution Channel
    • 14.7.7. Russia Market Analysis
      • 14.7.7.1. Introduction
      • 14.7.7.2. Market Analysis and Forecast, by Market Taxonomy
        • 14.7.7.2.1. By Product
        • 14.7.7.2.2. By Application
        • 14.7.7.2.3. By Distribution Channel

15. East Asia Market Analysis 2019-2023 and Forecast 2024-2033

  • 15.1. Introduction
  • 15.2. Historical Market Distribution Channel (US$ Mn) Trend Analysis, by Market Taxonomy, 2019-2023
  • 15.3. Current and Future Market Value (US$ Mn) Analysis and Forecast, by Market Taxonomy 2024-2033
    • 15.3.1. By Country
      • 15.3.1.1. China
      • 15.3.1.2. Japan
      • 15.3.1.3. South Korea
    • 15.3.2. By Product
    • 15.3.3. By Application
    • 15.3.4. By Distribution Channel
  • 15.4. Market Attractiveness Analysis
    • 15.4.1. By Product
    • 15.4.2. By Application
    • 15.4.3. By Distribution Channel
  • 15.5. Market Trends
  • 15.6. Drivers and Restraints - Impact Analysis
  • 15.7. Country Level Analysis & Forecast
    • 15.7.1. China Market Analysis
      • 15.7.1.1. Introduction
      • 15.7.1.2. Market Analysis and Forecast, by Market Taxonomy
        • 15.7.1.2.1. By Product
        • 15.7.1.2.2. By Application
        • 15.7.1.2.3. By Distribution Channel
    • 15.7.2. Japan Market Analysis
      • 15.7.2.1. Introduction
      • 15.7.2.2. Market Analysis and Forecast, by Market Taxonomy
        • 15.7.2.2.1. By Product
        • 15.7.2.2.2. By Application
        • 15.7.2.2.3. By Distribution Channel
    • 15.7.3. South Korea Market Analysis
      • 15.7.3.1. Introduction
      • 15.7.3.2. Market Analysis and Forecast, by Market Taxonomy
        • 15.7.3.2.1. By Product
        • 15.7.3.2.2. By Application
        • 15.7.3.2.3. By Distribution Channel

16. South Asia Market Analysis 2019-2023 and Forecast 2024-2033

  • 16.1. Introduction
  • 16.2. Historical Market Size (US$ Mn) Trend Analysis, by Market Taxonomy, 2019-2023
  • 16.3. Current and Future Market Value (US$ Mn) Analysis and Forecast, by Market Taxonomy 2024-2033
    • 16.3.1. By Country
      • 16.3.1.1. India
      • 16.3.1.2. Indonesia
      • 16.3.1.3. Malaysia
      • 16.3.1.4. Thailand
      • 16.3.1.5. Rest of South Asia
    • 16.3.2. By Product
    • 16.3.3. By Application
    • 16.3.4. By Distribution Channel
  • 16.4. Market Attractiveness Analysis
    • 16.4.1. By Country
    • 16.4.2. By Product
    • 16.4.3. By Application
    • 16.4.4. By Distribution Channel
  • 16.5. Market Trends
  • 16.6. Drivers and Restraints - Impact Analysis
  • 16.7. Country Level Analysis & Forecast
    • 16.7.1. India Market Analysis
      • 16.7.1.1. Introduction
      • 16.7.1.2. Market Analysis and Forecast, by Market Taxonomy
        • 16.7.1.2.1. By Product
        • 16.7.1.2.2. By Application
        • 16.7.1.2.3. By Distribution Channel
    • 16.7.2. Indonesia Market Analysis
      • 16.7.2.1. Introduction
      • 16.7.2.2. Market Analysis and Forecast, by Market Taxonomy
        • 16.7.2.2.1. By Product
        • 16.7.2.2.2. By Application
        • 16.7.2.2.3. By Distribution Channel
    • 16.7.3. Malaysia Market Analysis
      • 16.7.3.1. Introduction
      • 16.7.3.2. Market Analysis and Forecast, by Market Taxonomy
        • 16.7.3.2.1. By Product
        • 16.7.3.2.2. By Application
        • 16.7.3.2.3. By Distribution Channel
    • 16.7.4. Thailand Market Analysis
      • 16.7.4.1. Introduction
      • 16.7.4.2. Market Analysis and Forecast, by Market Taxonomy
        • 16.7.4.2.1. By Product
        • 16.7.4.2.2. By Application
        • 16.7.4.2.3. By Distribution Channel

17. Oceania Market 2019-2023 and Forecast 2024-2033

  • 17.1. Introduction
  • 17.2. Historical Market Size (US$ Mn) Trend Analysis, by Market Taxonomy, 2019-2023
  • 17.3. Current and Future Market Value (US$ Mn) Analysis and Forecast, by Market Taxonomy 2024-2033
    • 17.3.1. By Country
      • 17.3.1.1. Australia
      • 17.3.1.2. New Zealand
    • 17.3.2. By Product
    • 17.3.3. By Application
    • 17.3.4. By Distribution Channel
  • 17.4. Market Attractiveness Analysis
    • 17.4.1. By Country
    • 17.4.2. By Product
    • 17.4.3. By Application
    • 17.4.4. By Distribution Channel
  • 17.5. Market Trends
  • 17.6. Drivers and Restraints - Impact Analysis
  • 17.7. Country Level Analysis & Forecast
    • 17.7.1. Australia Market Analysis
      • 17.7.1.1. Introduction
      • 17.7.1.2. Market Analysis and Forecast, by Market Taxonomy
        • 17.7.1.2.1. By Product
        • 17.7.1.2.2. By Application
        • 17.7.1.2.3. By Distribution Channel
    • 17.7.2. New Zealand Market Analysis
      • 17.7.2.1. Introduction
      • 17.7.2.2. Market Analysis and Forecast, by Market Taxonomy
        • 17.7.2.2.1. By Product
        • 17.7.2.2.2. By Application
        • 17.7.2.2.3. By Distribution Channel

18. Middle East and Africa (MEA) Market Analysis 2019-2023 and Forecast 2024-2033

  • 18.1. Introduction
  • 18.2. Historical Market Size (US$ Mn) Trend Analysis, by Market Taxonomy, 2019-2023
  • 18.3. Current and Future Market Value (US$ Mn) Analysis and Forecast, by Market Taxonomy 2024-2033
    • 18.3.1. By Country
      • 18.3.1.1. GCC Countries
      • 18.3.1.2. Turkiye
      • 18.3.1.3. South Africa
      • 18.3.1.4. North Africa
      • 18.3.1.5. Rest of Middle East and Africa
    • 18.3.2. By Product
    • 18.3.3. By Application
    • 18.3.4. By Distribution Channel
  • 18.4. Market Attractiveness Analysis
    • 18.4.1. By Product
    • 18.4.2. By Application
    • 18.4.3. By Distribution Channel
  • 18.5. Market Trends
  • 18.6. Drivers and Restraints - Impact Analysis
  • 18.7. Country Level Analysis & Forecast
    • 18.7.1. GCC Countries Market Analysis
      • 18.7.1.1. Introduction
      • 18.7.1.2. Market Analysis and Forecast, by Market Taxonomy
        • 18.7.1.2.1. By Product
        • 18.7.1.2.2. By Application
        • 18.7.1.2.3. By Distribution Channel
    • 18.7.2. Turkiye Market Analysis
      • 18.7.2.1. Introduction
      • 18.7.2.2. Market Analysis and Forecast, by Market Taxonomy
        • 18.7.2.2.1. By Product
        • 18.7.2.2.2. By Application
        • 18.7.2.2.3. By Distribution Channel
    • 18.7.3. South Africa Market Analysis
      • 18.7.3.1. Introduction
      • 18.7.3.2. Market Analysis and Forecast, by Market Taxonomy
        • 18.7.3.2.1. By Product
        • 18.7.3.2.2. By Application
        • 18.7.3.2.3. By Distribution Channel
    • 18.7.4. North Africa Market Analysis
      • 18.7.4.1. Introduction
      • 18.7.4.2. Market Analysis and Forecast, by Market Taxonomy
        • 18.7.4.2.1. By Product
        • 18.7.4.2.2. By Application
        • 18.7.4.2.3. By Distribution Channel

19. Market Structure Analysis

  • 19.1. Market Analysis, by Tier of Companies
  • 19.2. Market Share Analysis of Top Players
  • 19.3. Market Presence Analysis

20. Competition Analysis

  • 20.1. Competition Dashboard
  • 20.2. Branding and Promotional Strategies
  • 20.3. Key Development Analysis
  • 20.4. Competition Deep Dive
    • 20.4.1. Novartis AG (Liposoma BV)
      • 20.4.1.1. Overview
      • 20.4.1.2. Product Portfolio
      • 20.4.1.3. Sales Footprint
      • 20.4.1.4. Key Financials
      • 20.4.1.5. SWOT Analysis
      • 20.4.1.6. Strategy Overview
        • 20.4.1.6.1. Marketing Strategy
        • 20.4.1.6.2. Product Strategy
        • 20.4.1.6.3. Channel Strategy
    • 20.4.2. Precision NanoSystems Inc
      • 20.4.2.1. Overview
      • 20.4.2.2. Product Portfolio
      • 20.4.2.3. Sales Footprint
      • 20.4.2.4. Key Financials
      • 20.4.2.5. SWOT Analysis
      • 20.4.2.6. Strategy Overview
        • 20.4.2.6.1. Marketing Strategy
        • 20.4.2.6.2. Product Strategy
        • 20.4.2.6.3. Channel Strategy
    • 20.4.3. Janssen Pharmaceutical Companies (Johnson & Johnson)
      • 20.4.3.1. Overview
      • 20.4.3.2. Product Portfolio
      • 20.4.3.3. Sales Footprint
      • 20.4.3.4. Key Financials
      • 20.4.3.5. SWOT Analysis
      • 20.4.3.6. Strategy Overview
        • 20.4.3.6.1. Marketing Strategy
        • 20.4.3.6.2. Product Strategy
        • 20.4.3.6.3. Channel Strategy
    • 20.4.4. Encapsula Nano Sciences
      • 20.4.4.1. Overview
      • 20.4.4.2. Product Portfolio
      • 20.4.4.3. Sales Footprint
      • 20.4.4.4. Key Financials
      • 20.4.4.5. SWOT Analysis
      • 20.4.4.6. Strategy Overview
        • 20.4.4.6.1. Marketing Strategy
        • 20.4.4.6.2. Product Strategy
        • 20.4.4.6.3. Channel Strategy
    • 20.4.5. Synpac-Kingdom Pharmaceutical Co., Ltd
      • 20.4.5.1. Overview
      • 20.4.5.2. Product Portfolio
      • 20.4.5.3. Sales Footprint
      • 20.4.5.4. Key Financials
      • 20.4.5.5. SWOT Analysis
      • 20.4.5.6. Strategy Overview
        • 20.4.5.6.1. Marketing Strategy
        • 20.4.5.6.2. Product Strategy
        • 20.4.5.6.3. Channel Strategy
    • 20.4.6. Celsion GmbH
      • 20.4.6.1. Overview
      • 20.4.6.2. Product Portfolio
      • 20.4.6.3. Sales Footprint
      • 20.4.6.4. Key Financials
      • 20.4.6.5. SWOT Analysis
      • 20.4.6.6. Strategy Overview
        • 20.4.6.6.1. Marketing Strategy
        • 20.4.6.6.2. Product Strategy
        • 20.4.6.6.3. Channel Strategy
    • 20.4.7. Gilead Sciences, Inc
      • 20.4.7.1. Overview
      • 20.4.7.2. Product Portfolio
      • 20.4.7.3. Sales Footprint
      • 20.4.7.4. Key Financials
      • 20.4.7.5. SWOT Analysis
      • 20.4.7.6. Strategy Overview
        • 20.4.7.6.1. Marketing Strategy
        • 20.4.7.6.2. Product Strategy
        • 20.4.7.6.3. Channel Strategy
    • 20.4.8. Pacira BioSciences, Inc.
      • 20.4.8.1. Overview
      • 20.4.8.2. Product Portfolio
      • 20.4.8.3. Sales Footprint
      • 20.4.8.4. Key Financials
      • 20.4.8.5. SWOT Analysis
      • 20.4.8.6. Strategy Overview
        • 20.4.8.6.1. Marketing Strategy
        • 20.4.8.6.2. Product Strategy
        • 20.4.8.6.3. Channel Strategy
    • 20.4.9. Luye Pharma Group
      • 20.4.9.1. Overview
      • 20.4.9.2. Product Portfolio
      • 20.4.9.3. Sales Footprint
      • 20.4.9.4. Key Financials
      • 20.4.9.5. SWOT Analysis
      • 20.4.9.6. Strategy Overview
        • 20.4.9.6.1. Marketing Strategy
        • 20.4.9.6.2. Product Strategy
        • 20.4.9.6.3. Channel Strategy
    • 20.4.10. Sun Pharma Industries Ltd
      • 20.4.10.1. Overview
      • 20.4.10.2. Product Portfolio
      • 20.4.10.3. Sales Footprint
      • 20.4.10.4. Key Financials
      • 20.4.10.5. SWOT Analysis
      • 20.4.10.6. Strategy Overview
        • 20.4.10.6.1. Marketing Strategy
        • 20.4.10.6.2. Product Strategy
        • 20.4.10.6.3. Channel Strategy
    • 20.4.11. Shanghai New Asia Pharmaceutical Co., Ltd.
      • 20.4.11.1. Overview
      • 20.4.11.2. Product Portfolio
      • 20.4.11.3. Sales Footprint
      • 20.4.11.4. Key Financials
      • 20.4.11.5. SWOT Analysis
      • 20.4.11.6. Strategy Overview
        • 20.4.11.6.1. Marketing Strategy
        • 20.4.11.6.2. Product Strategy
        • 20.4.11.6.3. Channel Strategy
    • 20.4.12. ENERGY DELIVERY SOLUTIONs
      • 20.4.12.1. Overview
      • 20.4.12.2. Product Portfolio
      • 20.4.12.3. Sales Footprint
      • 20.4.12.4. Key Financials
      • 20.4.12.5. SWOT Analysis
      • 20.4.12.6. Strategy Overview
        • 20.4.12.6.1. Marketing Strategy
        • 20.4.12.6.2. Product Strategy
        • 20.4.12.6.3. Channel Strategy
    • 20.4.13. Creative Biolabs
      • 20.4.13.1. Overview
      • 20.4.13.2. Product Portfolio
      • 20.4.13.3. Sales Footprint
      • 20.4.13.4. Key Financials
      • 20.4.13.5. SWOT Analysis
      • 20.4.13.6. Strategy Overview
        • 20.4.13.6.1. Marketing Strategy
        • 20.4.13.6.2. Product Strategy
        • 20.4.13.6.3. Channel Strategy
    • 20.4.14. Nanovex Biotechnologies SL
      • 20.4.14.1. Overview
      • 20.4.14.2. Product Portfolio
      • 20.4.14.3. Sales Footprint
      • 20.4.14.4. Key Financials
      • 20.4.14.5. SWOT Analysis
      • 20.4.14.6. Strategy Overview
        • 20.4.14.6.1. Marketing Strategy
        • 20.4.14.6.2. Product Strategy
        • 20.4.14.6.3. Channel Strategy
    • 20.4.15. Insys Therapeutics Inc
      • 20.4.15.1. Overview
      • 20.4.15.2. Product Portfolio
      • 20.4.15.3. Sales Footprint
      • 20.4.15.4. Key Financials
      • 20.4.15.5. SWOT Analysis
      • 20.4.15.6. Strategy Overview
        • 20.4.15.6.1. Marketing Strategy
        • 20.4.15.6.2. Product Strategy
        • 20.4.15.6.3. Channel Strategy
    • 20.4.16. Fujifilm Holdings Corporation
      • 20.4.16.1. Overview
      • 20.4.16.2. Product Portfolio
      • 20.4.16.3. Sales Footprint
      • 20.4.16.4. Key Financials
      • 20.4.16.5. SWOT Analysis
      • 20.4.16.6. Strategy Overview
        • 20.4.16.6.1. Marketing Strategy
        • 20.4.16.6.2. Product Strategy
        • 20.4.16.6.3. Channel Strategy
    • 20.4.17. Virpax Pharmaceuticals
      • 20.4.17.1. Overview
      • 20.4.17.2. Product Portfolio
      • 20.4.17.3. Sales Footprint
      • 20.4.17.4. Key Financials
      • 20.4.17.5. SWOT Analysis
      • 20.4.17.6. Strategy Overview
        • 20.4.17.6.1. Marketing Strategy
        • 20.4.17.6.2. Product Strategy
        • 20.4.17.6.3. Channel Strategy
    • 20.4.18. Azaya Therapeutics
      • 20.4.18.1. Overview
      • 20.4.18.2. Product Portfolio
      • 20.4.18.3. Sales Footprint
      • 20.4.18.4. Key Financials
      • 20.4.18.5. SWOT Analysis
      • 20.4.18.6. Strategy Overview
        • 20.4.18.6.1. Marketing Strategy
        • 20.4.18.6.2. Product Strategy
        • 20.4.18.6.3. Channel Strategy
    • 20.4.19. Avanti Polar Lipids, Inc.
      • 20.4.19.1. Overview
      • 20.4.19.2. Product Portfolio
      • 20.4.19.3. Sales Footprint
      • 20.4.19.4. Key Financials
      • 20.4.19.5. SWOT Analysis
      • 20.4.19.6. Strategy Overview
        • 20.4.19.6.1. Marketing Strategy
        • 20.4.19.6.2. Product Strategy
        • 20.4.19.6.3. Channel Strategy
    • 20.4.20. Breath Therapeutics (Zambon company)
      • 20.4.20.1. Overview
      • 20.4.20.2. Product Portfolio
      • 20.4.20.3. Sales Footprint
      • 20.4.20.4. Key Financials
      • 20.4.20.5. SWOT Analysis
      • 20.4.20.6. Strategy Overview
        • 20.4.20.6.1. Marketing Strategy
        • 20.4.20.6.2. Product Strategy
        • 20.4.20.6.3. Channel Strategy
    • 20.4.21. Getwell
      • 20.4.21.1. Overview
      • 20.4.21.2. Product Portfolio
      • 20.4.21.3. Sales Footprint
      • 20.4.21.4. Key Financials
      • 20.4.21.5. SWOT Analysis
      • 20.4.21.6. Strategy Overview
        • 20.4.21.6.1. Marketing Strategy
        • 20.4.21.6.2. Product Strategy
        • 20.4.21.6.3. Channel Strategy
    • 20.4.22. Taiwan Liposome Company Ltd
      • 20.4.22.1. Overview
      • 20.4.22.2. Product Portfolio
      • 20.4.22.3. Sales Footprint
      • 20.4.22.4. Key Financials
      • 20.4.22.5. SWOT Analysis
      • 20.4.22.6. Strategy Overview
        • 20.4.22.6.1. Marketing Strategy
        • 20.4.22.6.2. Product Strategy
        • 20.4.22.6.3. Channel Strategy
    • 20.4.23. Fresenius Health Care Group
      • 20.4.23.1. Overview
      • 20.4.23.2. Product Portfolio
      • 20.4.23.3. Sales Footprint
      • 20.4.23.4. Key Financials
      • 20.4.23.5. SWOT Analysis
      • 20.4.23.6. Strategy Overview
        • 20.4.23.6.1. Marketing Strategy
        • 20.4.23.6.2. Product Strategy
        • 20.4.23.6.3. Channel Strategy
    • 20.4.24. Xellia Pharmaceuticals (Novo Holdings A/S)
      • 20.4.24.1. Overview
      • 20.4.24.2. Product Portfolio
      • 20.4.24.3. Sales Footprint
      • 20.4.24.4. Key Financials
      • 20.4.24.5. SWOT Analysis
      • 20.4.24.6. Strategy Overview
        • 20.4.24.6.1. Marketing Strategy
        • 20.4.24.6.2. Product Strategy
        • 20.4.24.6.3. Channel Strategy
    • 20.4.25. Jazz Pharmaceuticals plc
      • 20.4.25.1. Overview
      • 20.4.25.2. Product Portfolio
      • 20.4.25.3. Sales Footprint
      • 20.4.25.4. Key Financials
      • 20.4.25.5. SWOT Analysis
      • 20.4.25.6. Strategy Overview
        • 20.4.25.6.1. Marketing Strategy
        • 20.4.25.6.2. Product Strategy
        • 20.4.25.6.3. Channel Strategy
    • 20.4.26. Ipsen Biopharmaceuticals, Inc.
      • 20.4.26.1. Overview
      • 20.4.26.2. Product Portfolio
      • 20.4.26.3. Sales Footprint
      • 20.4.26.4. Key Financials
      • 20.4.26.5. SWOT Analysis
      • 20.4.26.6. Strategy Overview
        • 20.4.26.6.1. Marketing Strategy
        • 20.4.26.6.2. Product Strategy
        • 20.4.26.6.3. Channel Strategy
    • 20.4.27. Baxter
      • 20.4.27.1. Overview
      • 20.4.27.2. Product Portfolio
      • 20.4.27.3. Sales Footprint
      • 20.4.27.4. Key Financials
      • 20.4.27.5. SWOT Analysis
      • 20.4.27.6. Strategy Overview
        • 20.4.27.6.1. Marketing Strategy
        • 20.4.27.6.2. Product Strategy
        • 20.4.27.6.3. Channel Strategy
    • 20.4.28. GMPriority Pharma
      • 20.4.28.1. Overview
      • 20.4.28.2. Product Portfolio
      • 20.4.28.3. Sales Footprint
      • 20.4.28.4. Key Financials
      • 20.4.28.5. SWOT Analysis
      • 20.4.28.6. Strategy Overview
        • 20.4.28.6.1. Marketing Strategy
        • 20.4.28.6.2. Product Strategy
        • 20.4.28.6.3. Channel Strategy
    • 20.4.29. S. G. Biopharm Pvt. Ltd
      • 20.4.29.1. Overview
      • 20.4.29.2. Product Portfolio
      • 20.4.29.3. Sales Footprint
      • 20.4.29.4. Key Financials
      • 20.4.29.5. SWOT Analysis
      • 20.4.29.6. Strategy Overview
        • 20.4.29.6.1. Marketing Strategy
        • 20.4.29.6.2. Product Strategy
        • 20.4.29.6.3. Channel Strategy

21. Assumptions and Acronyms Used

22. Research Methodology